Citius Pharmaceuticals, Inc.
CTXR · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $6 | $0 | $1 | $3 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $17 | $15 | $14 | $8 |
| Other Curr. Assets | $1 | $3 | $3 | $3 |
| Total Curr. Assets | $25 | $18 | $18 | $14 |
| Property Plant & Equip (Net) | $1 | $1 | $0 | $0 |
| Goodwill | $9 | $9 | $9 | $9 |
| Intangibles | $93 | $93 | $93 | $93 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $93 | $0 | $0 | $0 |
| Total NC Assets | $103 | $103 | $102 | $102 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $128 | $121 | $121 | $117 |
| Liabilities | – | – | – | – |
| Payables | $10 | $9 | $7 | $5 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $42 | $40 | $37 | $31 |
| Total Curr. Liab. | $52 | $50 | $45 | $36 |
| LT Debt | $1 | $1 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $8 | $7 | $7 | $7 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $8 | $8 | $7 | $7 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $1 | $1 | $0 | $0 |
| Total Liabilities | $60 | $58 | $52 | $43 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$231 | -$222 | -$211 | -$201 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $296 | $283 | $277 | $271 |
| Total Equity | $65 | $61 | $65 | $70 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $3 | $3 | $4 | $4 |
| Total Liab. & Tot. Equity | $128 | $121 | $121 | $117 |
| Net Debt | -$5 | $1 | -$1 | -$3 |